Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2026) 117 CC3 | DOI: 10.1530/endoabs.117.CC3

SFEBES2026 Featured Clinical Case Posters Section (10 abstracts)

CT-Guided Radiofrequency Ablation as a Novel Treatment for Adrenal Cushing's Syndrome in a High-Risk Surgical Candidate

Sophie Buckley , Laila Parvanta , Deborah Low , W.M. Drake & Mona Waterhouse


St Bartholomew’s Hospital, Barts Health NHS Trust, London, United Kingdom


A 44-year-old female with a history of left hepatectomy for a hydatid cyst was referred following an incidental finding of a 2.8 cm right adrenal adenoma on MRI liver imaging. She had recently developed hypertension and pre-diabetes, accompanied by a one-year history of symptoms consistent with Cushing’s syndrome. Initial investigations showed biochemistry consistent with a diagnosis of adrenal Cushing’s syndrome without evidence of co-secretion. Medical therapy with metyrapone was tolerated well and the patient reported a marked improvement in her symptoms with a return of menstruation. She was referred to the endocrine surgical team for consideration of a right adrenalectomy. On review of imaging, there was concern that the adrenal gland had adhered to the liver at the site of the previous surgery and a surgical approach was not without significant risk. Emerging evidence from the FABULAS trial supports the use of radiofrequency ablation (RFA) for aldosterone-secreting adrenal adenomas1. However, its application in cortisol-secreting lesions remains underreported. Given the patient’s surgical risk, CT-guided percutaneous RFA was performed under general anaesthesia in January 2025. The procedure was uncomplicated, and the patient was discharged on hydrocortisone. A 9 a.m. cortisol measured four days post-procedure (off hydrocortisone) was 28 nmol/l, confirming biochemical remission. Apart from transient infective complications, she has remained well on 7 mg prednisolone once daily. This case demonstrates the potential role of CT-guided RFA as a safe and effective alternative to surgery for functioning adrenal adenomas in patients unsuitable for surgical intervention. Further research is warranted to define its efficacy and long-term outcomes in cortisol-secreting adrenal tumours.

Reference 1. Argentesi et al (2025) ‘Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial’ The Lancet. 405, 10479 p637-647.

Volume 117

Society for Endocrinology BES 2026

Harrogate, United Kingdom
02 Mar 2026 - 04 Mar 2026

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches